Pathology: Obsessive Compulsive Disorder (OCD) Therapeutics

• Publication date: April 2012
• Report size: 71 pages

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry . The report identifies the major industry developments shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry . The report also provides insights on the prevalent competitive landscape and th...

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry . The report identifies the major industry developments shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Obsessive-Compulsive Disorder (OCD) Therapeutics segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

The report provides data on the key drivers and challenges of the Obsessive-Compulsive Disorder (OCD) Therapeutics industry . Its scope includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Obsessive-Compulsive Disorder (OCD) Therapeutics industry revenues data 2005-2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Obsessive-Compulsive Disorder (OCD) Therapeutics industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Obsessive-Compulsive Disorder (OCD) Therapeutics therapeutics industry .
- Analysis of key recent licensing and partnership agreements in Obsessive-Compulsive Disorder (OCD) Therapeutics industry

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Obsessive-Compulsive Disorder (OCD) Therapeutics industry landscape? – Identify, understand and decide.

Therapy Industry in the United Kingdom

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5

II OCD Therapeutics - Introduction 6
II. 1 Disease Data 6
II. 2 Epidemiology 6
II. 3 Etiology and Pathophysiology 7
II. 4 Signs and Symptoms 7
II. 5 Treatment 7
II. 6 Referral Pathway 8
II. 7 GlobalData Pipeline Report Guidance 9

III OCD Therapeutics - March ket Characterization 10
III. 1 OCD Therapeutics March ket Size (2005–2010) – World 10
III. 2 OCD Therapeutics March ket Forecasted data (2010–2017) – World 11
III. 3 OCD Therapeutics March ket Size (2005–2010) – The US 12
III. 4 OCD Therapeutics March ket Forecasted data (2010–2017) – The US 13
III. 5 OCD Therapeutics March ket Size (2005–2010) – France 14
III. 6 OCD Therapeutics March ket Forecasted data (2010–2017) – France 15
III. 7 OCD Therapeutics March ket Size (2005–2010) – Germany 16
III. 8 OCD Therapeutics March ket Forecasted data (2010–2017) – Germany 17
III. 9 OCD Therapeutics March ket Size (2005–2010) – Italy 18
III. 10 OCD Therapeutics March ket Forecasted data (2010–2017) – Italy 19
III. 11 OCD Therapeutics March ket Size (2005–2010) – Spain 20
III. 12 OCD Therapeutics March ket Forecasted data (2010–2017) – Spain 21
III. 13 OCD Therapeutics March ket Size (2005–2010) – The UK 22
III. 14 OCD Therapeutics March ket Forecasted data (2010–2017) – The UK 23
III. 15 OCD Therapeutics March ket Size (2005–2010) – Japan 24
III. 16 OCD Therapeutics March ket Forecasted data (2010–2017) – Japan 25
III. 17 Drivers and Barriers for the OCD Therapeutics March ket 26
III. 17.1 Drivers for the OCD Therapeutics March ket 26
III. 17.2 Barriers for the OCD Therapeutics March ket 26
III. 18 Opportunity and Unmet Need Analysis 27
III. 19 Key Takeaway 27

IV OCD Therapeutics - Competitive Assessment 28
IV. 1 Overview 28
IV. 2 Strategic Competitor Assessment 28
IV. 3 Product Profiles for the Major March keted Products in the OCD Therapeutics March ket 29
IV. 3.1 Paxil (paroxetine) 29
IV. 3.2 Zoloft (sertraline hydrochloride) 30
IV. 3.3 Luvox CR (fluvoxamine) 31
IV. 3.4 Prozac (fluoxetine hydrochloride) 32
IV. 3.5 Anafranil (clomipramine hydrochloride) 33
IV. 4 Key Takeaway 33

V OCD Therapeutics - Pipeline Assessment 34
V. 1 Overview 34
V. 2 Strategic Pipeline Assessment 34
V. 3 OCD Therapeutics Pipeline – Pipeline by Phases of Development 34
V. 3.1 OCD Therapeutics – Phase III Pipeline 34
V. 3.2 OCD Therapeutics – Phase II Pipeline 35
V. 3.3 OCD March ket – Discovery and Pre-clinical Pipeline 35
V. 3.4 Technology Trends Analytic Framework 36
V. 4 OCD Therapeutics March ket – Clinical Pipeline by Mechanism of Action 37
V. 5 OCD Therapeutics – Promising Drugs Under Clinical Development 37
V. 6 Molecule Profile for Promising Drugs Under Clinical Development 38
V. 6.1 Gamunex-C 38
V. 7 Key Takeaway 38

VI OCD Therapeutics - Clinical Trials Mapping 39
VI. 1 Clinical Trials by Region/Country (US, EU5 and Japan) 39
VI. 2 Clinical Trials by Phase 40
VI. 3 Clinical Trials by Trial Status 41
VI. 4 Key Sponsors 42
VI. 5 Top Firms Participating in OCD Therapeutics Clinical Trials 44

VII Strategic Assessment 45
VII. 1 Key Events Impacting the Future March ket 45
VII. 2 OCD Therapeutics - Implications for Future March ket Competition 46

VIII OCD Therapeutics - Future Players 47
VIII. 1 Introduction 47
VIII. 2 Firms Profiles 48
VIII. 2.1 Transcept Pharmaceuticals, Inc. 48

IX OCD Therapeutics - Licensing and Partnership Deals 49

X OCD Therapeutics - Appendix 50
X. 1 March ket Definitions 50
X. 2 Abbreviations 50
X. 2.1 Methodology 50
X. 2.2 Coverage 51
X. 2.3 Secondary Research 51
X. 2.4 Forecasted data ing 51
X. 2.5 Primary Research 54
X. 2.6 Expert Panel Validation 54
X. 3 Contact Us 54
X. 4 Disclaimer 54
X. 5 Bibliography 55

1.1

List of Tables


Data table 1: Common Obsessions in OCD 6
Data table 2: OCD Therapeutics March ket, Global, Sales (USD Million), 2005–2010 10
Data table 3: OCD Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 11
Data table 4: OCD Therapeutics March ket, The US, Sales (USD Million), 2005–2010 12
Data table 5: OCD Therapeutics March ket, The US, Forecasted data s (USD Million), 2010–2017 13
Data table 6: OCD Therapeutics March ket, France, Sales (USD Million), 2005–2010 14
Data table 7: OCD Therapeutics March ket, France, Forecasted data s (USD Million), 2010–2017 15
Data table 8: OCD Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 16
Data table 9: OCD Therapeutics March ket, Germany, Forecasted data s (USD Million), 2010–2017 17
Data table 10: OCD Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 18
Data table 11: OCD Therapeutics March ket, Italy, Forecasted data s (USD Million), 2010–2017 19
Data table 12: OCD Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 20
Data table 13: OCD Therapeutics March ket, Spain, Forecasted data s (USD Million), 2010–2017 21
Data table 14: OCD Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 22
Data table 15: OCD Therapeutics March ket, The UK, Forecasted data s (USD Million), 2010–2017 23
Data table 16: OCD Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 24
Data table 17: OCD Therapeutics March ket, Japan, Forecasted data s (USD Million), 2010–2017 25
Data table 18: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 29
Data table 19: Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 32
Data table 20: OCD Therapeutics, Phase III Pipeline, 2011 34
Data table 21: OCD Therapeutics, Phase II Pipeline, 2011 35
Data table 22: OCD Therapeutics, Discovery and Preclinical Pipeline, 2011 35
Data table 23: OCD Therapeutics – Most Promising Drugs Under Clinical Development, 2011 37
Data table 24: OCD Therapeutics, Clinical Trials by Country, 2011 39
Data table 25: OCD Therapeutics – Clinical Trials by Phase, 2011 40
Data table 26: OCD Therapeutics, Clinical Trials by Status (%), 2011 41
Data table 27: OCD Therapeutics, Key Sponsors, 2011 43
Data table 28: OCD Therapeutics, Top Firms Participating in Therapeutics Clinical Trials, 2011 44
Data table 29: Transcept Pharmaceuticals Inc., Product Pipeline, 2011 48
Data table 30: OCD Therapeutics, Global, Deals, from 2010 to 2011 49

1.2

List of Figures


Chart 1: OCD Therapeutics Drug Dosage Pattern 7
Chart 2: Referral Pathway for Obsessive Compulsive Disorders 8
Chart 3: OCD Therapeutics March ket, Global, Sales (USD Million), 2005–2010 10
Chart 4: OCD Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 11
Chart 5: OCD Therapeutics March ket, The US, Sales (USD Million), 2005–2010 12
Chart 6: OCD Therapeutics March ket, The US, Forecasted data (USD Million), 2010–2017 13
Chart 7: OCD Therapeutics March ket, France, Sales (USD Million), 2005–2010 14
Chart 8: OCD Therapeutics March ket, France, Forecasted data (USD Million), 2010–2017 15
Chart 9: OCD Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 16
Chart 10: OCD Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 17
Chart 11: OCD Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 18
Chart 12: OCD Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 19
Chart 13: OCD Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 20
Chart 14: OCD Therapeutics March ket, Spain, Forecasted data (USD Million), 2010–2017 21
Chart 15: OCD Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 22
Chart 16: OCD Therapeutics March ket, The UK, Forecasted data (USD Million), 2010–2017 23
Chart 17: OCD Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 24
Chart 18: OCD Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 25
Chart 19: Opportunity and Unmet Need in the OCD Therapeutics March ket, 2010 27
Chart 20: OCD Therapeutics, Strategic Competitor Assessment, 2010 28
Chart 21: OCD Therapeutics – Pipeline by Phase of Development, 2011 34
Chart 22: OCD Therapeutics, Technology Trends Analytics Framework, 2011 36
Chart 23: OCD Therapeutics, Technology Trends Analytics Framework, Description, 2011 36
Chart 24: OCD Therapeutics, Pipeline by Mechanism of Action (%), 2011 37
Chart 25: Gamunex-C Clinical Trial Details 38
Chart 26: OCD Therapeutics, Clinical Trials by Country, 2011 39
Chart 27: OCD Therapeutics, Clinical Trials by Phase (%), 2011 40
Chart 28: OCD Therapeutics, Clinical Trials by Status (%), 2011 41
Chart 29: OCD Therapeutics, Overall Sponsors (%), 2011 42
Chart 30: OCD Therapeutics, Key Sponsors (%), 2011 43
Chart 31: OCD Therapeutics, Top Firms Participating in Clinical Trials, 2011 44
Chart 32: OCD Therapeutics March ket, Drivers and Restraints, 2011 45
Chart 33: Implications for Future March ket Competition in the OCD March ket, 2011 46
Chart 34: OCD Therapeutics March ket, Pipeline by Firms, 2011 47
Chart 35: GlobalData March ket Forecasted data ing Model 53

Companies Mentioned
Transcept Pharmaceuticals, Inc.